Physician profile
James C Mathews
NPI 1477523140
$1,376.61
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $385 · 2021: $20.04 · 2022: $34.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $206.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $198.32 | 2019-2020 | |
| Astellas Pharma US INC | $136.25 | 2019-2022 | |
| Grifols USA, LLC | $130.64 | 2019-2021 | |
| Amgen INC. | $122.05 | 2019 | |
| Amarin Pharma, INC. | $90.23 | 2019-2020 | |
| Pfizer INC. | $86.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $73.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $56.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.14 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $33.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $33.01 | 2019 | |
| Sanofi Pasteur INC. | $25.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.49 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24.88 | 2019 | |
| Strongbridge US INC. | $15.10 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2020 | |
| Circassia INC. | $11.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.